Clinical Trial Update: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase II clinical trial evaluating chlorambucil with subcutaneous rituximab in patients with extranodal MALT lymphoma; the study status is Active Not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Drugs mentioned

• Chlorambucil (chlorambucil)
• Rituximab (rituximab)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: MALT Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING